Cempra Inc (CEMP) 27.68 $CEMP
Retirement Planning - Cramer's Mad Money (2/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 09, 6:48AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, February 6. This earnings season has been a vast disappointment. Cramer believes that terrible earnings now is good, as it sets the bar really low for the year....
WFM: 56.15 (-0.15), TSLA: 203.77 (+0.89), HAL: 44.19 (+1.42), VFC: 75.26 (+4.26), MAS: 26.45 (+0.02), VTR: 76.61 (-0.41), PEP: 99.13 (-1.14), WWAV: 38.65 (+0.61), DNB: 133.27 (+0.46), CVS: 102.63 (-0.37), CEMP: 27.68 (+1.25), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), BHI: 64.31 (+1.93)
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue Feb 03, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 27.68 (+1.25)
Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jan 16, 8:54AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 27.68 (+1.25)
Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock
GlobeNewswire - Tue Jan 13, 3:01PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 5,250,000 shares of common stock, plus an additional 787,500 shares issued pursuant to the full exercise by the underwriters of their option to purchase additional shares at a public offering price of $24.50 per share. The full exercise of the option increases the net proceeds to the company, after underwriting discounts and commissions and expected expenses of the offering expenses, from approximately $120.6 million to approximately $138.7 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
Cempra Has Insider Interest And A Blockbuster Anti-Biotic: Buy
Value Insight - at Seeking Alpha - Tue Jan 13, 7:55AM CST
JNJ: 99.62 (+1.18), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Does Cempra Have The Next Blockbuster Drug?
TipRanks - at Seeking Alpha - Fri Jan 09, 10:31AM CST
By Sarah Roden Pharmaceutical company Cempra (NASDAQ: CEMP ) creates antibiotics to treat bacterial infections. The company produces Solithromycin, a treatment for community-acquired bacterial pneumonia that is now is Phase III testing. Investors...
CEMP: 27.68 (+1.25)
Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:41AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 27.68 (+1.25)
Stocks Coverage on the Pharma Industry -- Mylan, Salix Pharma, Zoetis, Theravance, and Cempra
PR Newswire - Fri Jan 09, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Zoetis Inc. (NYSE: ZTS), Theravance Inc. (NASDAQ: THRX), and Cempra Inc. (NASDAQ: CEMP). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, January 08, 2015, the NASDAQ Composite ended at 4,736.19, up 1.84%, the Dow Jones Industrial Average advanced 1.84%, to finish the day at 17,907.87, and the S&P 500 closed at 2,062.14, up 1.79%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index also advancing 3.75% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ZTS: 45.46 (-0.33), THRXV: 28.00 (+7.07), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), CEMP: 27.68 (+1.25), THRX: 14.85 (+1.00)
Cempra prices offering
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:42PM CST
CEMP: 27.68 (+1.25)
Cempra Prices Public Offering of Common Stock
GlobeNewswire - Wed Jan 07, 7:00PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has priced an underwritten public offering of 5,250,000 shares of its common stock at a price of $24.50 per share for aggregate gross proceeds of approximately $128.6 million. Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $120.6 million. The company also has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares, which would result in additional net proceeds of approximately $18.1 million, if exercised in full. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses. The offering is expected to close on or about January 13, 2015, subject to satisfaction of customary closing conditions.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:44AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares gain over 7%
ACRX: 7.29 (-0.06), CEMP: 27.68 (+1.25)
Cempra plans secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:29PM CST
CEMP: 27.68 (+1.25)
Cempra Reports Positive Results on Antibiotic Solithromycin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 4:25PM CST
Cempra, Inc. (CEMP) announced positive top-line results from a phase III study on pipeline candidate solithromycin. Cempra is evaluating solithromycin for the treatment of community-acquired bacterial pneumonia (CABP).
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CEMP: 27.68 (+1.25), BIOD: 1.38 (-0.14)
Brutal Day for Stocks as Crude Oil's Crash Bleeds Energy Sector Dry
at The Street - Mon Jan 05, 4:05PM CST
It was a brutal day on Wall Street as crude oil plunged below $50 a barrel, punishing oil stocks and dealing a hefty blow to the broader stock market.
HK: 2.18 (-0.02), F: 16.30 (-0.06), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SBUX: 91.58 (-0.24), RDS.A: 66.32 (+0.97), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CAT: 85.13 (+1.60), CEMP: 27.68 (+1.25), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
Cempra Announces Proposed Public Offering of $100 Million of Common Stock
GlobeNewswire - Mon Jan 05, 3:39PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering with an aggregate public offering price of approximately $15 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
S&P 500 Drops to Mid-December Levels as Crude Drops Below $50
at The Street - Mon Jan 05, 2:33PM CST
Crude prices continue to plummet, punishing oil stocks and dealing a hefty blow to the broader stock market on Monday.
HK: 2.18 (-0.02), F: 16.30 (-0.06), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SBUX: 91.58 (-0.24), RDS.A: 66.32 (+0.97), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CEMP: 27.68 (+1.25), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
Energy Stocks Suffer Heavy Losses as Oil Prices Drop Below $51
at The Street - Mon Jan 05, 9:53AM CST
Stock are lower early Monday as the price of crude oil drops below $51 a barrel, a fresh 5 1/2-year low.
HK: 2.18 (-0.02), F: 16.30 (-0.06), PLUG: 3.15 (unch), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SO: 45.88 (-0.68), RDS.A: 66.32 (+0.97), RIG: 19.05 (+0.42), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CEMP: 27.68 (+1.25), GPS: 41.20 (-0.37), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
Retirement Planning - Cramer's Mad Money (2/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 09, 6:48AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, February 6. This earnings season has been a vast disappointment. Cramer believes that terrible earnings now is good, as it sets the bar really low for the year....
WFM: 56.15 (-0.15), TSLA: 203.77 (+0.89), HAL: 44.19 (+1.42), VFC: 75.26 (+4.26), MAS: 26.45 (+0.02), VTR: 76.61 (-0.41), PEP: 99.13 (-1.14), WWAV: 38.65 (+0.61), DNB: 133.27 (+0.46), CVS: 102.63 (-0.37), CEMP: 27.68 (+1.25), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), BHI: 64.31 (+1.93)
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue Feb 03, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 27.68 (+1.25)
Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jan 16, 8:54AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 27.68 (+1.25)
Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock
GlobeNewswire - Tue Jan 13, 3:01PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 5,250,000 shares of common stock, plus an additional 787,500 shares issued pursuant to the full exercise by the underwriters of their option to purchase additional shares at a public offering price of $24.50 per share. The full exercise of the option increases the net proceeds to the company, after underwriting discounts and commissions and expected expenses of the offering expenses, from approximately $120.6 million to approximately $138.7 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
Cempra Has Insider Interest And A Blockbuster Anti-Biotic: Buy
Value Insight - at Seeking Alpha - Tue Jan 13, 7:55AM CST
JNJ: 99.62 (+1.18), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Does Cempra Have The Next Blockbuster Drug?
TipRanks - at Seeking Alpha - Fri Jan 09, 10:31AM CST
By Sarah Roden Pharmaceutical company Cempra (NASDAQ: CEMP ) creates antibiotics to treat bacterial infections. The company produces Solithromycin, a treatment for community-acquired bacterial pneumonia that is now is Phase III testing. Investors...
CEMP: 27.68 (+1.25)
Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:41AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 27.68 (+1.25)
Stocks Coverage on the Pharma Industry -- Mylan, Salix Pharma, Zoetis, Theravance, and Cempra
PR Newswire - Fri Jan 09, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Zoetis Inc. (NYSE: ZTS), Theravance Inc. (NASDAQ: THRX), and Cempra Inc. (NASDAQ: CEMP). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, January 08, 2015, the NASDAQ Composite ended at 4,736.19, up 1.84%, the Dow Jones Industrial Average advanced 1.84%, to finish the day at 17,907.87, and the S&P 500 closed at 2,062.14, up 1.79%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index also advancing 3.75% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ZTS: 45.46 (-0.33), THRXV: 28.00 (+7.07), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), CEMP: 27.68 (+1.25), THRX: 14.85 (+1.00)
Cempra prices offering
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:42PM CST
CEMP: 27.68 (+1.25)
Cempra Prices Public Offering of Common Stock
GlobeNewswire - Wed Jan 07, 7:00PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has priced an underwritten public offering of 5,250,000 shares of its common stock at a price of $24.50 per share for aggregate gross proceeds of approximately $128.6 million. Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $120.6 million. The company also has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares, which would result in additional net proceeds of approximately $18.1 million, if exercised in full. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses. The offering is expected to close on or about January 13, 2015, subject to satisfaction of customary closing conditions.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:44AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares gain over 7%
ACRX: 7.29 (-0.06), CEMP: 27.68 (+1.25)
Cempra plans secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:29PM CST
CEMP: 27.68 (+1.25)
Cempra Reports Positive Results on Antibiotic Solithromycin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 4:25PM CST
Cempra, Inc. (CEMP) announced positive top-line results from a phase III study on pipeline candidate solithromycin. Cempra is evaluating solithromycin for the treatment of community-acquired bacterial pneumonia (CABP).
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CEMP: 27.68 (+1.25), BIOD: 1.38 (-0.14)
Brutal Day for Stocks as Crude Oil's Crash Bleeds Energy Sector Dry
at The Street - Mon Jan 05, 4:05PM CST
It was a brutal day on Wall Street as crude oil plunged below $50 a barrel, punishing oil stocks and dealing a hefty blow to the broader stock market.
HK: 2.18 (-0.02), F: 16.30 (-0.06), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SBUX: 91.58 (-0.24), RDS.A: 66.32 (+0.97), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CAT: 85.13 (+1.60), CEMP: 27.68 (+1.25), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
Cempra Announces Proposed Public Offering of $100 Million of Common Stock
GlobeNewswire - Mon Jan 05, 3:39PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering with an aggregate public offering price of approximately $15 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CEMP: 27.68 (+1.25), MS: 36.78 (-0.12)
S&P 500 Drops to Mid-December Levels as Crude Drops Below $50
at The Street - Mon Jan 05, 2:33PM CST
Crude prices continue to plummet, punishing oil stocks and dealing a hefty blow to the broader stock market on Monday.
HK: 2.18 (-0.02), F: 16.30 (-0.06), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SBUX: 91.58 (-0.24), RDS.A: 66.32 (+0.97), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CEMP: 27.68 (+1.25), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
Energy Stocks Suffer Heavy Losses as Oil Prices Drop Below $51
at The Street - Mon Jan 05, 9:53AM CST
Stock are lower early Monday as the price of crude oil drops below $51 a barrel, a fresh 5 1/2-year low.
HK: 2.18 (-0.02), F: 16.30 (-0.06), PLUG: 3.15 (unch), XOM: 93.37 (+1.00), PDS: 6.04 (+0.12), FCAU: 14.53 (+0.06), SO: 45.88 (-0.68), RDS.A: 66.32 (+0.97), RIG: 19.05 (+0.42), GM: 37.62 (-0.40), BP: 41.93 (+0.59), CEMP: 27.68 (+1.25), GPS: 41.20 (-0.37), CVX: 112.78 (+1.92), HMC: 32.87 (+0.14), OAS: 16.84 (-0.03), XLE: 82.04 (+1.70)
